Stock Events

Stock Events

Skye Bioscience 

€1.7752
36
+€0.04+2.45% 13:50 Today

Statistics

Day High
1.8188
Day Low
1.8188
52W High
1.8188
52W Low
1.7328
Volume
72
Avg. Volume
-
Mkt Cap
7.86M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q2 2026
Next
-1.87
-1.72
-1.58
-1.44
Expected EPS
-1.437459552
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 09R0.F. It's not an investment recommendation.
NVIDIA
8
NVDA
Microsoft
7
MSFT
Apple
6
AAPL
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap200.76M
Corbus Pharmaceuticals works on developing and commercializing novel therapeutics to treat inflammatory and fibrotic diseases, overlapping with some of Skye Bioscience's therapeutic targets.
Aurora Cannabis
ACB
Mkt Cap249.44M
Aurora Cannabis is a major player in the cannabis industry, and while primarily focused on recreational and medicinal cannabis products, its interest in medical research could position it as a competitor in cannabinoid therapeutics.
Tilray Brands
TLRY
Mkt Cap665.89M
Tilray is engaged in pharmaceutical-grade cannabis research, cultivation, processing, and distribution, making it a competitor in the cannabinoid-based pharmaceuticals market.
Canopy Growth
CGC
Mkt Cap471.76M
Canopy Growth Corporation operates in the cannabis and hemp-based consumer product markets but also invests in research and development for cannabinoid-based medicines.
Curaleaf
CURLF
Mkt Cap2.5B
Curaleaf Holdings operates in the cannabis retail and medical cannabis markets, and its involvement in developing cannabis-based medicinal products makes it a competitor in the cannabinoid therapeutics field.

About

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Show more...
CEO
Punit Dhillon
Employees
12
Country
United States
ISIN
US83086J3095
WKN
000A42JP2

Listings

MU
DE
09R0.MU
F
DE
09R0.F
STU
DE
09R0.STU
XNAS
US
SKYE

0 Comments

Share your thoughts

FAQ

What is Skye Bioscience stock price today?▼
The current price of 09R0.F is €1.78 EUR — it has increased by +2.45% in the past 24 hours. Watch Skye Bioscience stock price performance more closely on the chart.
What is Skye Bioscience stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Skye Bioscience stocks are traded under the ticker 09R0.F.
What is Skye Bioscience market cap?▼
Today Skye Bioscience has the market capitalization of 7.86M
When is the next Skye Bioscience earnings date?▼
Skye Bioscience is going to release the next earnings report on November 05, 2026.
What were Skye Bioscience earnings last quarter?▼
09R0.F earnings for the last quarter are -1.87 EUR per share, whereas the estimation was -1.76 EUR resulting in a -5.9% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Skye Bioscience have?▼
As of August 25, 2026, the company has 12 employees.
In which sector is Skye Bioscience located?▼
Skye Bioscience operates in the Health & Wellness sector.
When did Skye Bioscience complete a stock split?▼
Skye Bioscience has not had any recent stock splits.
Where is Skye Bioscience headquartered?▼
Skye Bioscience is headquartered in SAN DIEGO, United States.